ArticleTranslational lung cancer research2025
PD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pleural mesothelioma (PM) is an uncommon malignancy with a poor prognosis, even after surgical resection. Programmed death-ligand 1 (PD-L1) expression is a potential prognostic biomarker in various cancers, yet its role in PM patients undergoing pleurectomy/decortication (P/D) is unclear. This study aimed to evaluate the prognostic significance of PD-L1 expression in patients with PM who underwent P/D. Methods: This retrospective study included patients with PM who underwent P/D from 2012 to 2022. PD-L1 expression in tumor cells was evaluated by immunohistochemistry, categorizing patients by tumor proportion score (TPS): 0%, 1-49%, and ≥50%. Survival outcomes were assessed using Kaplan-Meier curves and Cox proportional hazards regression models. Results: A total of 58 patients were enrolled in the study. The median overall survival (OS) was 77.0 months for TPS 0%, 41.0 months for TPS 1-49%, and 25.3 months for TPS ≥50%. The corresponding relapse-free survival (RFS) was 34.3, 13.2, and 6.7 months, respectively. Lower PD-L1 expression was significantly associated with improved outcomes (OS: P=0.041, RFS: P=0.002). In multivariable analysis, PD-L1 TPS 0% ( Conclusions: Our findings suggest that PD-L1 expression levels in tumor cells may influence postoperative prognosis and relapse risk in patients with PM undergoing P/D. Lower PD-L1 expression correlates with improved survival outcomes, positioning PD-L1 as a potential biomarker to inform therapeutic strategies in this population. Further studies are warranted to explore the implications of PD-L1 in treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.